CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of results from the MACI® (autologous cultured chondrocytes on porcine collagen membrane) Phase 3 SUMMIT  Extension Study in the American Journal of Sports Medicine.  The results […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone